All In Biotech

Drug Trial Radar · NCT05142592

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Nov 15, 2021

Primary completion

Feb 8, 2026

Study completion Mar 5, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The study will include a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2a). Each part will consist of a screening period of up to 28 days, a treatment period, an end of treatment visit and a safety follow-up of approximately 30 days after the last dose. IPG7236 will be given on an empty stomach (either one hour before or two hours after a meal) twice daily (approximately every 12±1 hours) in continuous 28-day cycles.

Conditions

  • Safety Issues
  • Tolerability
  • Pharmacokinetics

Interventions

  • IPG7236Drug

    The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of all adverse eventsTime frame: Up to 33 days
  2. Maximum tolerated dose (MTD)Time frame: Up to 33 days
  3. Phase II dose (RP2D)Time frame: Up to 33 days
  4. Disease Control Rate(DCR)Time frame: up to 1 year(anticipated)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Providence Portland Medical Center

    Portland, Oregon

  • NEXT Oncology

    Austin, Texas

  • Shanghai East Hospital

    Shanghai, China

  • Shanghai General Hospital

    Shanghai, China

  • Shanghai GoBroad Cancer Hospital China Pharmaceutical University

    Shanghai, China

  • The First Affiliated Hospital Nanchang Univeristy

    Nanchang, Jiangxi, China

  • Shandong Cancer Hospital

    Jinan, Shangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.